IN8bio cuts staff and pipeline to focus on AML cell therapy - Clinical Trials Arena

September 6, 2024

IN8bio reduces headcount by 49% and suspends glioblastoma programme to focus on AML cell therapy INB-100, aiming for a registrational trial. The board and management team also cut cash compensation by 11%. IN8bio plans to add a control cohort to its ongoing Phase I trial and expand the Phase II dose cohort, with enrolment expected by H1 2025.

Related Clinical Trials

Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients with Newly Diagnosed Glioblastoma

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Reference News

clinicaltrialsarena.com

IN8bio cuts staff and pipeline to focus on AML cell therapy - Clinical Trials Arena